US FDA's Califf On Real-World Evidence: 'Use It For The Right Purposes'
This article was originally published in SRA
Randomized clinical trials have long been extolled as the gold standard for establishing drug efficacy and safety. However, US Food and Drug Administration Commissioner Robert Califf has his sights set on increased use of another type of research for informing regulatory decision-making: randomized clinical practice studies.
You may also be interested in...
Agency is eager to engage with sponsors on ‘well thought-out proposals' to include real-world data sources in randomized studies, Office of New Drugs director Peter Stein says but adds that believability and robustness of the data are the agency’s primary concern.
Advisory committee votes 24-2 against approval of Intellipharmaceutics’ Aximris XR due to concerns the extended-release oxycodone formulation may be more susceptible to intranasal abuse than existing products; Esteve fares better with its tramadol/celecoxib combination, securing a tie vote on approval for acute pain.
Although abuse by intravenous route is expected to be deterred compared to immediate-release oxycodone, neither nasal nor oral abuse deterrence was demonstrated in two new human abuse potential studies, agency concludes; product has a new formulation and a new name, Aximris XR, since a 2017 AdComm.